Education
About Us
Working with TipRanks
Follow Us
Cardiff Oncology, Inc. (CRDF)
NASDAQ:CRDF
Top Page
Cardiff Oncology
(NASDAQ:CRDF)
Select Model
Select Model
Rating:48Neutral
Price Target:
$2.50
▼(-11.03% Downside)
The score is held down primarily by weak financial performance (minimal revenue, large ongoing losses, and significant cash burn), partially offset by low leverage. Technical indicators are modestly supportive in the near term (positive MACD; price above shorter-term averages), but the stock remains below its 200-day average. Valuation provides limited support due to a negative P/E and no dividend yield.
Positive Factors
Positive Clinical Trial Results
The successful phase 2 trial results enhance Cardiff Oncology's product pipeline credibility and potential market entry, strengthening its competitive position in oncology.
Strong Cash Position
A robust cash position provides Cardiff Oncology with the financial flexibility to continue R&D activities and clinical trials, supporting long-term growth and stability.
Strategic Leadership Changes
The appointment of an experienced CMO can drive strategic clinical development, potentially accelerating drug approval processes and enhancing market positioning.
Negative Factors
Negative Cash Flow
Persistent negative cash flow indicates ongoing operational inefficiencies, which could hinder Cardiff Oncology's ability to sustain operations without external financing.
Declining Revenue
Decreasing revenue reflects challenges in generating income from operations, raising concerns about the company's ability to achieve financial independence and growth.
High Operational Losses
Significant operational losses highlight inefficiencies and the need for improved cost management, which could impact long-term profitability and sustainability.
Cardiff Oncology (CRDF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$189.28M
Dividend YieldN/A
Average Volume (3M)1.02M
Price to Earnings (P/E)―
Beta (1Y)1.25
Revenue Growth-27.29%
EPS Growth16.40%
CountryUS
Employees32
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.17
Shares Outstanding67,360,565
10 Day Avg. Volume909,383
30 Day Avg. Volume1,017,957
Financial Highlights & Ratios
PEG Ratio-2.12
Price to Book (P/B)2.49
Price to Sales (P/S)302.78
P/FCF Ratio-5.47
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$13.67Price Target Upside386.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.76
Revenue Forecast (FY)$366.11K
Cardiff Oncology Business Overview & Revenue Model
Company DescriptionCardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
How the Company Makes MoneyCardiff Oncology makes money through a combination of funding sources typical of clinical-stage biotech companies, such as equity financing, grants, and strategic partnerships. As a company focused on drug development, Cardiff Oncology does not yet generate revenue from product sales. Instead, it relies on raising capital through public and private offerings of its stock to fund its research and development activities. Additionally, the company may receive milestone payments or licensing fees from collaborations with larger pharmaceutical companies interested in its drug candidates. These partnerships can provide crucial financial support and resources needed to advance their clinical trials and bring their products closer to commercialization.
Cardiff Oncology Earnings Call Summary
Earnings Call Date:Feb 27, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Feb 26, 2026
Earnings Call Sentiment Positive
The earnings call highlighted strong initial clinical data, successful capital raising efforts, and a solid financial position. However, some dependency on future FDA meetings and the early stage of PFS data might pose challenges. Overall, the sentiment is optimistic with clear progress, yet some uncertainties remain.Q4-2024 Updates
Positive Updates
Encouraging Initial Data from CRDF-004 Trial
The trial showed a 64% ORR for patients on the 30 mg dose of onvansertib, compared to a 33% ORR in the control arm, indicating a strong efficacy signal.
Successful Capital Raise
Cardiff Oncology successfully completed a $40 million capital raise, enhancing financial stability and resources for future developments.
Advancement in Intellectual Property
A new patent was issued covering the use of onvansertib with bevacizumab for KRAS-mutated mCRC, extending intellectual property protection until at least 2043.
Strong Financial Position
Cash and short-term investments totaled $91.7 million, providing a financial runway into Q1 2027.
Positive Preclinical Results in Breast Cancer
Onvansertib showed promising results in preclinical studies, demonstrating synergistic activity with paclitaxel and ENHERTU in drug-resistant HR-positive breast cancer models.
Negative Updates
Pending FDA Discussions
While progress has been made, key decisions regarding dose selection and trial design depend on future FDA meetings, which could impact timelines.
Limited Data on Progression-Free Survival (PFS)
It is too early to report PFS data from the CRDF-004 trial, leaving uncertainty about long-term efficacy and potential for full approval.
Company Guidance
During the Cardiff Oncology Fourth Quarter 2024 Financial Results and Business Update Conference Call, guidance was provided on several key metrics and future plans for the company. The company highlighted an initial data set from the CRDF-004 trial, which showed a 64% overall response rate (ORR) for patients on the 30 mg dose of onvansertib, compared to 33% in the control arm. The trial focuses on first-line RAS-mutated metastatic colorectal cancer (mCRC), and aims to complete enrollment of 90 evaluable patients in early 2025. The company plans to release additional clinical data in the first half of 2025. Financially, Cardiff Oncology reported $91.7 million in cash and short-term investments as of December 31, 2024, following a $40 million capital raise. The company projects that these resources will support operations into the first quarter of 2027, with a quarterly cash burn of $10.3 million in Q4 2024. Additionally, Cardiff Oncology strengthened its intellectual property portfolio with a new patent for onvansertib, expected to expire no earlier than 2043.Cardiff Oncology Financial Statement Overview
Summary
Cardiff Oncology faces significant financial hurdles with declining revenues and substantial operational losses. While the balance sheet shows minimal leverage, the company's dependence on external financing and negative cash flows are concerning for long-term viability.Income Statement
The company has been experiencing declining revenue over the recent periods, with a TTM revenue of $588,000 compared to $683,000 in the previous year. Gross profit margin for TTM is 65.8%, indicating decent cost management relative to revenue. However, significant net losses are a concern, with a net profit margin of -8309.18% for TTM, reflecting high operational inefficiencies. The EBIT and EBITDA margins are deeply negative, indicating ongoing operational challenges.12
Very Negative
Balance Sheet
The balance sheet reveals a strong equity position with a debt-to-equity ratio of 0.02, suggesting minimal leverage. The equity ratio stands at 83.5% for TTM, indicating a solid financial foundation with most assets financed by equity. However, the company's consistent net losses are eroding equity, which could present long-term risks.63
Positive
Cash Flow
Operating cash flow remains negative at -$42.7 million for TTM, indicating cash outflows in core operations. The company is heavily reliant on financing activities to sustain operations, as evidenced by a substantial cash inflow from financing. The free cash flow is also negative, aligning with the operational losses, which raises concerns about sustainable cash generation.18
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 501.00K | 683.00K | 488.00K | 386.00K | 359.00K | 366.00K |
| Gross Profit | -11.08M | 683.00K | 488.00K | 386.00K | 359.00K | 366.00K |
| EBITDA | -52.08M | -48.25M | -45.01M | -39.67M | -28.40M | -18.84M |
| Net Income | -50.42M | -45.43M | -41.44M | -38.70M | -28.29M | -19.31M |
Balance Sheet | ||||||
| Total Assets | 63.78M | 97.19M | 81.64M | 116.19M | 149.54M | 134.73M |
| Cash, Cash Equivalents and Short-Term Investments | 60.59M | 91.75M | 74.82M | 105.27M | 140.82M | 130.98M |
| Total Debt | 1.01M | 1.52M | 2.15M | 2.71M | 3.12M | 869.00K |
| Total Liabilities | 14.99M | 14.24M | 11.90M | 9.85M | 9.13M | 6.57M |
| Stockholders Equity | 48.79M | 82.95M | 69.74M | 106.34M | 140.42M | 128.16M |
Cash Flow | ||||||
| Free Cash Flow | -42.27M | -37.77M | -31.47M | -34.71M | -23.25M | -16.53M |
| Operating Cash Flow | -42.22M | -37.69M | -30.89M | -33.82M | -23.04M | -16.32M |
| Investing Cash Flow | -4.90M | 13.73M | 36.20M | 38.15M | -131.45M | -211.00K |
| Financing Cash Flow | 44.22M | 53.78M | 0.00 | 75.00K | 35.45M | 137.31M |
Cardiff Oncology Technical Analysis
Neutral
2.81
Price Trends
2.47
Positive
2.32
Positive
2.72
Positive
Market Momentum
0.14
Positive
52.09
Neutral
34.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRDF, the sentiment is Neutral. The current price of 2.81 is below the 20-day moving average (MA) of 2.86, above the 50-day MA of 2.47, and above the 200-day MA of 2.72, indicating a neutral trend. The MACD of 0.14 indicates Positive momentum. The RSI at 52.09 is Neutral, neither overbought nor oversold. The STOCH value of 34.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CRDF.
Cardiff Oncology Risk Analysis
Cardiff Oncology disclosed 53 risk factors in its most recent earnings report. Cardiff Oncology reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cardiff Oncology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $189.28M | -3.52 | -102.71% | ― | -27.29% | 16.40% | |
47 Neutral | $299.72M | -1.79 | -174.79% | ― | -76.59% | 94.03% | |
47 Neutral | $123.91M | -1.16 | -87.28% | ― | -82.53% | -52.00% | |
43 Neutral | $112.99M | -3.46 | -745.66% | ― | ― | ― | |
42 Neutral | $167.41M | -2.24 | -49.86% | ― | -100.00% | 11.02% |
* Healthcare Sector Average
CRDF
Cardiff Oncology
2.79
-0.61
-17.94%
ONCY
Oncolytics Biotech
0.97
0.14
16.11%
AVTX
Avalo Therapeutics
15.64
8.91
132.39%
GLSI
Greenwich LifeSciences
29.29
16.72
133.02%
MOLN
Molecular Partners
4.21
-1.60
-27.54%
PYXS
Pyxis Oncology
1.99
0.52
35.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.